EptinezuMaB in ReAl-world evidenCE: a 12-Months, Multicenter, Real-Life, Cohort Study in High-Frequency Episodic and Chronic Migraine (the EMBRACE Study)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age between 18 and 75 years;
• Males and females;
• Willingness to sign the informed consent;
• High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
• Chronic migraine, according to the ICHD-III criteria;
Locations
Other Locations
Italy
IRCCS San Raffaele Roma
RECRUITING
Roma
Contact Information
Primary
Piero Barbanti, MD, PhD
piero.barbanti@sanraffaele.it
+393357071457
Backup
Cinzia Aurilia, MD
cinzia.aurilia@sanraffaele.it
+393334147390
Time Frame
Start Date: 2023-01-01
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 500
Related Therapeutic Areas
Sponsors
Leads: IRCCS San Raffaele Roma